ARC Trinova is acquiring site in Alnwick to form International Contract Research and Development Business.
Arc Trinova, a new company formed by Ian Shott and Paul Ryan, owners of Shott Trinova LLP, is delighted to announce the successful acquisition of the Covance Alnwick site in Northumberland, United Kingdom.The Alnwick site has focused primarily on activities that fall within the Chemistry Manufacturing and Controls (CMC) area of pharmaceutical development and this will be continued in full. Arc Trinova will add capability in Active Pharmaceutical Ingredient (API) process development and scale up to the multi-kilogram level. The new business will continue to offer Covance these services while also seeking to build a large international client base. The company will aim to deliver best in class technology in the fields of contract research, development and small scale manufacturing to maximise effectiveness whilst minimising risk and overall cost. Arc Trinova has a long term vision to grow a large and sustainable business offering this broad array of services to customers all over the world.
Ian Shott and Paul Ryan, both residents in the North East of England, have worked together for the last 15 years running businesses that operate in the global pharmaceutical market.Managing Director Ian Shott commented: “The Company considers the Alnwick site to be a large very well equipped facility that is perfectly designed to accommodate the full range of capabilities envisaged, with a staff of the highest calibre providing a strong internationally competitive platform for sustainable growth in the future”.
"The agreement with Arc Trinova provides a future for the Alnwick site and many of its staff and allows us to collaborate with Arc Trinova in certain areas linked to work performed at other Covance sites,” says Steve Street, General Manager and Global Vice President Early Development. He adds “The non-clinical business remains a key component of drug development within Covance.”
Bond Dickinson provided lead legal advice and Alistair Scott-Somers, Corporate Partner at Bond Dickinson’s Leeds office, commented: “Working with experienced deal makers like Ian Shott and Paul Ryan has been a pleasure and to be instrumental in securing the future of a business which is a key employer in the North East has been very rewarding”.
The Company has also received financial advice for this transaction from LGF Partners, a specialist debt advisory business focused on providing independent, strategic and creative debt capital raising advice to companies and management teams in the high technology and fast growth sectors. The firm raises debt capital for SME and small to mid-cap businesses in the UK, Ireland, Europe and further a field.
About Arc Trinova
We are a Contract Research, Development and Manufacturing Organisation (CRDO) providing the pharmaceutical industry with comprehensive services from drug R&D through small scale manufacture.
We are focused on providing services linked to the pre-clinical to Phase I/IIa clinical development of new small molecules drug candidates, Process Development, Scale-Up and Manufacturing, covering drug candidates in Development and launched to the Market, at relatively small quantities.
We are trusted partners for our customers supporting their development and delivery programmes for new medicines in a timely and cost effective manner to sustainably improve the health and wellbeing of society.
Our mission is to deliver best in class technology services in the fields of contract research, development and small scale manufacturing to maximise effectiveness whilst minimising risk and overall cost.
Discover how Arcinova can help
We provide a fully integrated approach to drug development, speak to our team and discover how we can help you fast forward to market.